Efficacy and safety of risankizumab in psoriasis patients who failed anti‐IL‐17, anti‐12/23 and/or anti IL‐23: preliminary data of a real‐life 16‐week retrospective study

Up until now, real-life experiences on the efficacy of risankizumab in patients who had previously failed anti-IL17, anti-IL12/23 or anti-IL23 inhibitor are not reported. We carried out a single-centre, retrospective study, to evaluate the efficacy, safety and tolerability of patients under risankizumab who previously failed anti-IL17, anti-IL12/23 or anti-IL23 inhibitors in a real-life setting. A total of 8 patients were enrolled (4 men and 4 women, mean age 45.8 ± 14.3 years). Five of them (62.5%) had received ustekinumab, 7 (87.5%) at least one anti-IL17, and only one (12.5%) patient guselkumab. Secukinumab had been used in 5 (62.5%) cases, and ixekizumab in 4 (50.0%). Baseline mean PASI and BSA were 11.9 ± 5.5, and 22.9 ± 13.1, respectively, and 3.3±1.7 and 7.5 ± 5 (P<0.001 and P<0.01) at week 16. Mean baseline NAPSI (18.0 ± 8.5) reduced to 7 ± 1.4 at week 16. Palmo-plantar and scalp area showed a reduction of 67.5% and 99.9% at week 16, respectively. No AEs was reported. Real-life preliminary data show risankizumab as a promising therapeutic option in patients who failed anti-IL-17, anti-IL12/23 and even the other anti-IL-23 counterpart, guselkumab. This article is protected by copyright. All rights reserved.